tbuckley/cabot-search huggingface dataset:
258P Immune checkpoint inhibitors addition to chemotherapy in older patients with metastatic triple-negative breast cancer: A systematic review and meta-analysis
Authors: M. Pagliuca, L. Bencivenga, K. Komici, C. De Angelis, R. Caputo, F. Napolitano, D. Cianniello, V. Di Lauro, G. Rengo, S. de Placido, F. André, M. De Laurentiis
Journal: Annals of Oncology (2022)
221P Early prediction of efficacy of endocrine therapy (ET) in metastatic breast cancer (MBC): Pilot study with [18F]fluoro-estradiol-17β (18F-FES) PET/CT
Authors: A. Gennari, E.G.C. Brain, O. Nanni, N. Harbeck, J. Cortés, A. De Censi, A. Piccardo, J.L. Alberini, F. Matteucci, G. Sacchetti, H. Ilhan, M. Monti, R. Wuerlestein, C. Saggia, V. Rossi, F. D'Avanzo, P.M. Maggiora, M. Iacozzi, A. Frassoldati, L. Boni
Journal: Annals of Oncology (2022)
343P DPYD gene sequencing and in silico functionality prediction of polymorphisms in 3,471 colorectal cancer patients treated with fluoropyrimidine (FP)
Authors: M-C. Etienne-Grimaldi, J-C.C. Boyer, E. Menoret, J-P. Desvignes, V. Boige, J. Taieb, P. Laurent-Puig, Y.A. Wettergren, M. Schwab, S.P. Ackland, B. Jennings, E. Seutin, J. Rousset, G. Le Teuff, N. Cozic, Y. Koudou, C. Béroud
Journal: Annals of Oncology (2022)
509P COVID-19 disease among lung cancer (LC) patients: Data from a real-life prospective multicentric study
Authors: O. Molinier, L. Falchero, I. Monnet, C. Decroisette, A-C. Neidhart, E. Redureau, A-M. Chiappa, F. Bigot, A. Bedossa, K. Amrane, S. Jeandeau, C. Dujon, A-S. Bugnet, P. Bonnefoy, C. Alizon, N. Meyer, S. Couraud, A. Cortot, A. Letierce, D. Debieuvre
Journal: Annals of Oncology (2022)
222P BYLieve trial (alpelisib [ALP] + endocrine therapy [ET]) versus real-world (RW) standard of care (SOC) in patients (Pts) with PIK3CA-mutated (Mut), hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) who progressed on cyclin-dependent kinase 4/6 inhibitor (CDKi) therapy (Tx)
Journal: Annals of Oncology (2022)
1033P IMreal Cohort 2: Second interim analysis of efficacy and safety data in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) under real-world conditions
Authors: N. Girard, S. Popat, S. Shoshkova, S. Fear, J.L. Perez Gracia
Journal: Annals of Oncology (2022)
59P Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications
Authors: M. Borad, M. Javle, W.L. Shaib, K. Mody, F. Bergamo, W.P. Harris, N. Damjanov, T. Macarulla, G. Brandi, G. Masi, M. Droz Dit Busset, A. Boncompagni, M. Dimova-Dobreva, M. Engelhardt, M. Saulay, T.R. Halfdanarson, J. Knox, G.K. Abou-Alfa, N. Personeni, V. Mazzaferro
Journal: Annals of Oncology (2022)
456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors
Authors: S. Postel-Vinay, A. Italiano, P. Martin Romano, P.A. Cassier, L.L. Siu, I.S. Lossos, J.F. Hilton, M.A. Mckean, J. Strauss, G.S. Falchook, M.J.A. de Jonge, F.L. Opdam, D. Rasco, J.S. Vermaat, T. Crossman, M. Zajac, A. Hainline, B. Kremer, O. Barbash, M.M. Gounder
Journal: Annals of Oncology (2022)
735MO Updated safety and efficacy from SURPASS, the phase I trial of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in previously treated patients with unresectable or metastatic tumors
Authors: D.S. Hong, A. Asch, E. Calvo, J. Zugazagoitia, J. Charlson, M.O. Butler, V. Moreno Garcia, A. Cervantes, B.A. Van Tine, D.P. Lawrence, M.L. Johnson, Q. Lin, T. Annareddy, F. Brophy, R. Broad, A. Derrac Soria, J-M. Navenot, J. Saro, E. Norry, J.M. Clarke
Journal: Annals of Oncology (2022)
546P Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158
Authors: D. O'Malley, G.M. Bariani, P.A. Cassier, A. Marabelle, A.R. Hansen, A. De Jesus-Acosta, W.H. Miller, T. Safra, A. Italiano, L. Mileshkin, L. Yao, A. Gozman, F.J. Jin, M. Maio
Journal: Annals of Oncology (2022)
958P Intensity-modulated radiotherapy (IMRT)-adapted chemoradiotherapy (CRT) followed by durvalumab for locally advanced non-small cell lung cancer (NSCLC): A multicenter prospective observational study (WJOG12019L)
Authors: N. Mamesaya, H. Harada, A. Hata, M. Konno, K. Nakamatsu, H. Hayashi, T. Yamamoto, R. Saito, H. Mayahara, M. Kokubo, Y. Sato, K. Yoshimura, Y. Nishimura, N. Yamamoto, K. Nakagawa
Journal: Annals of Oncology (2022)
933MO Longitudinal monitoring of circulating tumor DNA from plasma in patients with curative resected stage IA-IIIA EGFR mutant non-small cell lung cancer
Authors: M-J. Ahn, H.A. Jung, B.M. Ku, Y.J. Kim, S. Park, J-M. Sun, S-H. Lee, J.S. Ahn, J.H. Cho, H.K. Kim, Y.S. Choi, J. Kim
Journal: Annals of Oncology (2022)
349P Analysis of plasma angiogenesis factors on the efficacy of 2nd-line (2L) chemotherapy (chemo) combined with angiogenesis inhibitors (AIs) in metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study
Authors: S. Yuki, K. Yamazaki, Y. Sunakawa, H. Taniguchi, T. Masuishi, M. Shiozawa, H. Bando, T. Nishina, H. Yasui, T. Ohta, N. Takahashi, T. Denda, K. Yoshida, T. Kato, E. Oki, Y. Okugawa, H. Ebi, Y. Abe, S. Nomura, T. Yoshino
Journal: Annals of Oncology (2022)
159P Peripheral T-lymphocytes senescence and response to neoadjuvant therapy (NAT) in operable breast cancer (BC)
Authors: F. D'Avanzo, V. Rossi, C. Saggia, F. Platini, G. Borra, V. Martini, A. Rua, E. Gioffi, C. Branni, P.M. Maggiora, A. Tassone, F.M. Varughese, A. Ram Vachanaram, R. Ben Ayed, C. Angelillo, A. Barcellini, R. Boldorini, I. Dodaro, D. Ferrante, A. Gennari
Journal: Annals of Oncology (2022)
137MO Effect of peri-tumoral infiltration of local anaesthetic prior to surgery on survival in early breast cancer
Authors: R. Badwe, V. Parmar, N.S. Nair, R. Hawaldar, S. Joshi, S. Pawar, G. Kadayaprath, B. Borthakur, S. Rao, S. Pandya, S. B, P. Chitale, R. Neve, C. Harris, A. Srivastava, S. Siddique, V. Vanmali, A. Dewade, V. Gaikwad, S. Gupta
Journal: Annals of Oncology (2022)
72P Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET+ colorectal carcinoma as a unique molecular subset of CRC
Authors: M. Nagasaka, D. Brazel, Y. Baca, J. Xiu, M.N. Al-Hallak, C. Kim, J.J. Nieva, J.J. Swensen, D. Spetzler, W.M. Korn, M.A. Socinski, B. Halmos, S-H.I. Ou
Journal: Annals of Oncology (2022)
66O MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors
Authors: C. Friedman, C. Swanton, D. Spigel, R. Bose, H. Burris, W. Yu, Y. Wang, J. Malato, R. Price, W. Darbonne, T. Szado, K. Schulze, C. Sweeney, J. Hainsworth, F. Meric-Bernstam, R. Kurzrock
Journal: Annals of Oncology (2022)
986P Response to capmatinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) and MET exon 14 skipping (METex14) mutation: Whole transcriptome analysis from phase II GEOMETRY Mono-1 study
Authors: J. Wolf, H.J.M. Groen, D.S.W. Tan, E.B. Garon, D. Demanse, A. Robeva, A. Yovine, L. Fairchild, A.D. Boran, R. Heist
Journal: Annals of Oncology (2022)
417P Randomized phase II trial of upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy versus preoperative chemoradiotherapy followed by surgery and adjuvant chemotherapy in locally advanced rectal cancer: KCSG-CO14-10
Authors: S-H. Beom, S.H. Park, J.B. Ahn, H.S. Kim, S.J. Shin, K.Y. Lee, B.S. Min, N.K. Kim, T. Kim
Journal: Annals of Oncology (2022)
751P Preclinical evaluation of SG-3-06686, a positive allosteric modulator of CXCR3
Authors: H. Kiefel, J. Guagua, D. Haria, J. Lee, E. Casey, K. Roskamp, M. Willcoxon, K. Dabbagh, J. Dal Porto
Journal: Annals of Oncology (2022)
382P Sequential RAS mutation status evaluation in circulating free DNA (cfDNA) in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) starting first-line (1L) treatment with panitumumab (P) and chemotherapy (CT). PERSEIDA (Idylla Cohort) study
Authors: M. Valladares, M.J. Safont Aguileria, E. González-Flores, P. García Alfonso, A.M. López Muñoz, E. Aranda Aguilar, E. Falco Ferrer, N. Rodriguez-Salas, L. Cirera, M. Llanos-Munoz, J. Aparicio, P. Pimentel, A.O. Castillo Trujillo, M. Salgado Fernandez, M.A. Salud Salvia, R. Vidal Tocino, B. Massuti Sureda, R. Garcia-Carbonero, M.A.D.L.A. Vicente Conesa, A. Lloansi Vila
Journal: Annals of Oncology (2022)
495TiP A phase II study evaluating the safety and efficacy of ENV-101 (taladegib) in patients with advanced solid tumors harboring PTCH1 loss of function mutations
Authors: J.J. Luke, S. Pendyala, A. Di Francesco, S. Kim, L. Dellamary, S. KC, H. Humphreys, M. De Los Rios, J. Pitman, J. Hood, D.S. Hong
Journal: Annals of Oncology (2022)
427P Targeting adenosine (ADO) to improve the efficacy of combinations of cetuximab (CET) and immunotherapy in EGFRvIII MSS colorectal cancer (CRC)
Authors: M. Shi, F. Sun, F. Yao, S. Li, Y. Zhao, B. Liang, Q. Wu, X. Rong, Z. Yao, X. Xu, J. Wang, C. Zeng, G. Chen, Q. Huang, W. Liao
Journal: Annals of Oncology (2022)
440TiP TRESBIEN (OGSG 2101): Encorafenib, binimetinib and cetuximab for early relapse stage II/III BRAF V600E-mutated CRC
Authors: S. Boku, H. Satake, T. Ohta, S. Mitani, K. Kawakami, T. Matsumoto, E. Yamazaki, H. Hasegawa, T. Ikoma, M. Uemura, T. Yamaguchi, Y. Ishizuka, Y. Kurokawa, D. Sakai, H. Kawakami, T. Shimokawa, T. Tsujinaka, T. Kato, T. Satoh, Y. Kagawa
Journal: Annals of Oncology (2022)
390P Impact of age on treatment strategies in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): A prespecified subgroup analysis of the GERCOR-PRODIGE STRATEGIC-1 phase III study
Authors: E. Carola, B. Chibaudel, R. Boulahssass, L.M. Dourthe, T. André, J. Henriques, V. Bourgeois, P-L. Etienne, J. Desrame, O. Dupuis, N. Baba-Hamed, D. Auby, C. Louvet, E. Maillard, C. Tournigand, M-L. Garcia-Larnicol, E. Shacham Shmueli, B.H. Bird, F. Ghiringhelli, A. de Gramont
Journal: Annals of Oncology (2022)
746P Synergistic antitumor efficacy of INV-71 ROR gamma agonist with immune checkpoint inhibitor anti-PD-1 in a murine orthotopic 4T1 breast cancer model
Authors: C. Sebesta, V. Chung, A.B. El-Khoueiry, J. Tilley, W. Windsor, T. Stouch, J. Ellingboe, C. Zhang, A. Gaweco
Journal: Annals of Oncology (2022)
1022P A phase II study of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed first line treatment
Authors: C. Zhou, None A. Xiong, J. Fang, X. Li, Y. Fan, W. Zhuang, Q. Xie, Z. Ma, M. Kang, T. Xu, M. Xu, L. Zhi, Q. Liu, N. Wang
Journal: Annals of Oncology (2022)
264P Increased membrane HER3 expression in brain metastases compared to primary tumors in breast cancer
Authors: S. Kusuhara, T. Kogawa, M. Shimokawa, C. Funasaka, C.N. Kondoh, K. Harano, N. Matsubara, Y. Naito, A. Hosono, K. Satomi, M. Yoshida, S. Fujii, T. Ohnishi, A. Suto, K. Yonemori, K. Koyama, N. Maeda, Y. Narita, T. Mukohara
Journal: Annals of Oncology (2022)
635P The treatment patterns and outcomes in patients with AL amyloidosis: A multi-center, retrospective, observational, real-world study in Sichuan province, China
Authors: H. Yu, C. Zhang, Q. Liu, Y. Yang, J. Li, K. Wan, B. Cao, Y. Chen, H. Shang, Z. Hu, W. Liu, Y. Wu
Journal: Annals of Oncology (2022)
738P Combined ipilimumab and nivolumab in previously treated patients with cancer of unknown primary: Results of the CheCUP trial
Authors: M. Pouyiourou, B. Kraft, T. Wohlfromm, M. Stahl, B. Kubuschok, H. Löffler, U.T. Hacker, G. Huebner, C.B. Westphalen, M. Bitzer, T. Ernst, P. Schuett, T. Hielscher, S. Delorme, A. Stenzinger, T. Bochtler, A. Krämer
Journal: Annals of Oncology (2022)
903O A prospective study of a multi-cancer early detection blood test
Authors: D. Schrag, C.H. McDonnell, L. Nadauld, C.A. Dilaveri, E.A. Klein, R. Reid, C.R. Marinac, K.C. Chung, M. Lopatin, E.T. Fung, T.M. Beer
Journal: Annals of Oncology (2022)
597P Endometrial carcinoma and mismatch repair deficiency: Clinical association and universal screening for Lynch syndrome
Authors: S. Puglisi, M. Ponzano, M. Perachino, C. Pirrone, A. Damassi, G. Bregni, A. Puccini, M. Grassi, L. Trevisan, V. Gismondi, M. Dono, S. Lastraioli, P. Fedele, M. Cremante, A. Gandini, F. Giannelli, S. Mammoliti, V.G. Vellone, M.S. Sciallero, M.L. Iaia
Journal: Annals of Oncology (2022)
577P Impact of homologous recombination deficiency (HRD) on outcomes with intraperitoneal (IP) and intravenous (IV) chemotherapy in ovarian cancer: Analyses from the translational iPocc study (TriPocc)
Authors: S.T. Wijaya, T.Z. Tan, N.Y.L. Ngoi, A. Yabuno, K. Takehara, H. Nakazawa, T. Hirasawa, H. Fujiwara, M. Yasuda, Y-H. Jan, S-J. Chen, R.Y-J. Huang, K. Fujiwara, K. Hasegawa, D.S. Tan
Journal: Annals of Oncology (2022)
887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial
Authors: E. Baudin, T.A. Walter, A. Beron, D. Smith, J. Hadoux, C. Lachachi, D. Taieb, C. Ansquer, L.O. Dierickx, L. de Mestier du Bourg, E. Deshayes, E. Quak, L. Dahan, R. Guimbaud, Y. Touchefeu, M. Haissaguerre, C. Do Cao, C. Lombard Bohas, M. Attard, S. Foulon
Journal: Annals of Oncology (2022)
517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial
Authors: P. DiSilvestro, S. Banerjee, N. Colombo, G. Scambia, B-G. Kim, A. Oaknin, M.L. Friedlander, A.S. Lisyanskaya, A. Floquet, A. Leary, G.S. Sonke, C. Gourley, A.M. Oza, A.J. Gonzalez Martin, C. Aghajanian, W.H. Bradley, C. Mathews, J. McNamara, E. Lowe, K.N. Moore
Journal: Annals of Oncology (2022)
582P Longitudinal, multi-sample characterization of HGSC from DECIDER: A Finnish observational study
Authors: J. Oikkonen, A. Virtanen, Y. Li, V-M. Isoviita, K. Zhang, S. Jamalzadeh, G. Marchi, A. Häkkinen, T.A. Muranen, A. Lahtinen, S. Hietanen, K. Huhtinen, J. Hynninen, S. Hautaniemi
Journal: Annals of Oncology (2022)
944P Hazard function analysis of recurrence in patients with curatively resected lung cancer: Results from the Japanese Lung Cancer Registry in 2010
Authors: Y. Yamauchi, M. Kawamura, J. Okami, Y. Shintani, H. Ito, T. Ohtsuka, S. Toyooka, T. Mori, S-I. Watanabe, H. Asamura, M. Chida, S. Endo, M. Kadokura, R. Nakanishi, E. Miyaoka, I. Yoshino, H. Date
Journal: Annals of Oncology (2022)
994P Efficacy and safety of capmatinib plus spartalizumab in treatment-naïve patients with advanced NSCLC harboring MET exon 14 skipping mutation
Authors: J. Wolf, R. Heist, T.M. Kim, M. Nishio, C. Dooms, R.R. Kanthala, E. Leo, E. Giorgetti, Y. Wang, F.I. Mardjuadi, A. Cortot
Journal: Annals of Oncology (2022)
997P Phase I study of brigatinib plus panitumumab in patients with advanced EGFR-mutated non-small cell lung cancer resistant to osimertinib (BEBOP): Early termination due to severe early onset pneumonitis by brigatinib
Authors: H. Izumi, T. Sakamoto, K. Uchibori, K. Nishino, J. Sakakibara-Konishi, S. Nomura, K. Ryohei, H. Udagawa, Y. Shibata, T. Ikeda, S. Niho, T. Sakai, Y. Zenke, K. Nosaki, S. Matsumoto, K. Yoh, K. Goto
Journal: Annals of Oncology (2022)
85P A circulating, surrogate-systemic biomarker correlates with anti-tumor benefit on LNS8801 therapy
Authors: J. Cohen, C.A. Natale, J.J. Lin, P. Lorusso, A. Mita, M. Mita, C.Y. Muller, M. Orloff, K.P. Papadopoulos, J. Rodon, T.K. Garyantes
Journal: Annals of Oncology (2022)
854P Clinical features of acquired resistance (AR) in stage IV melanoma patients (pts) treated with immune checkpoint inhibition (ICI)
Authors: J.M. Versluis, E. Alofs, H.V. van Thienen, S. Wilgenhof, A. Meerveld-Eggink, H. Mallo, W. Uyterlinde, J. Lijnsvelt, J.B.A.G. Haanen, C.U. Blank
Journal: Annals of Oncology (2022)
844P Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody
Authors: J. Larkin, S. Dalle, M.F. Sanmamed, M. Wilson, J.C. Hassel, H. Kluger, M. Orloff, J.S. Weber, F. Graf Finckenstein, P. Hari, M. Jagasia, H. Yin, W. Shi, G. Sulur, X. Wu, V. Gontcharova, K. Lewis
Journal: Annals of Oncology (2022)
781TiP AGADIR: A basket multicenter open-label phase II study evaluating the first in class TLR7/8 agonist BDB001 in combination with atezolizumab and stereotactic body radiation therapy in patients with advanced solid tumors
Authors: A. Italiano, C. Coutzac Bergouignan, D. Pasquier, P. Rochigneux, M.P. Sablin, C.A. Gomez-Roca, F. Ghiringhelli, J-P. Metges, M. Toulmonde, S. Cousin, S. Pernot, C. Auzanneau, B. Lortal, M. Kind, P. Sargos, S. Batard, A. Petit, P. Gillon, S. Albert, M. Pulido
Journal: Annals of Oncology (2022)
527MO Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study
Authors: R. Kristeleit, S. Ghamande, M-C. Lim, C. Parkinson, M. Morgan, M. Wilson, A. Oaknin, J. Buscema, P. Bessette, D. Lorusso, F. Ueland, T. Safra, J. Barlin, F. Marmé, T.J. Herzog, I. McNeish, S. Goble, S. Hume, K. Fujiwara, B.J. Monk
Journal: Annals of Oncology (2022)
1019P Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial
Authors: M.R. Garcia Campelo, E. Felip, B. Besse, M. Cobo Dols, E. Quoix, A-C. Madroszyk Flandin, F. Cappuzzo, F. Denis, W. Hilgers, G. Romano, D. Debieuvre, D. Galetta, E. Baldini, S. Viteri Ramirez, M. Duc Phan, W. Schuette, A. Zer, B. Vasseur, R. Dziadziuszko, G. Giaccone
Journal: Annals of Oncology (2022)
733MO γδT cells are effectors of immune checkpoint blockade in mismatch repair-deficient colon cancers with antigen presentation defects
Authors: J. Van De Haar, N.L. de Vries, V. Veninga, M. Chalabi, M. Ijsselsteijn, M. van der Ploeg, J. van den Bulk, D. Ruano, J.B.A.G. Haanen, T.N. Schumacher, L.F.A. Wessels, F. Koning, N.F.C.C. de Miranda, E.E. Voest
Journal: Annals of Oncology (2022)
592P Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer
Authors: U.A. Matulonis, K.N. Moore, D. Lorusso, A. Oaknin, S. Pignata, H. Denys, N. Colombo, T. Van Gorp, J. Konner, M. Romeo Marin, P. Harter, C. Murphy, Y. Tu, F. Zhu, B. Esteves, M. Method, M.J. Birrer, R.L. Coleman, D. O'Malley
Journal: Annals of Oncology (2022)
466P Efficacy of BRAF inhibitor FORE8394 in BRAF V600+ patients
Authors: E.J. Sherman, F. Tsai, F. Janku, C. Allen, R. Yaeger, N. Ammakkanavar, N. Butowski, G. Michelson, M. Paz, A. Tussay-Lindenberg, K. Wang, S. Shepherd, E. Dehan, M. de la Fuente, J. Rodon
Journal: Annals of Oncology (2022)
1049P Clinical outcomes in patients (pts) with tumor PD-L1 &lt; 1% with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA
Authors: T. John, T-E. Ciuleanu, M. Cobo Dols, M. Schenker, B. Zurawski, J. Menezes, E.A. Richardet, J. Bennouna, Y. Cheng, E. Felip, O.J. Juan Vidal, A. Alexandru, L. Paz-Ares, S. Lu, M. Reck, N. Hu, X. Zhang, D.J. Grootendorst, L. Eccles, D.P. Carbone
Journal: Annals of Oncology (2022)
418P Colorectal cancer lung metastases resection and its impact on survival in the oligometastatic setting
Authors: J.C. Ruffinelli Rodriguez, E. Guinó, A. Ruiz Valderrama, G. Ibañez, I. Macia Vidueira, S. Padrones Sanchez, A. Navarro Martin, C. Santos Vivas
Journal: Annals of Oncology (2022)
316O Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study
Authors: S. Kopetz, D.A. Murphy, J. Pu, R. Yaeger, F. Ciardiello, J. Desai, E. Van Cutsem, H.S. Wasan, T. Yoshino, B. Alkuzweny, T. Xie, X. Zhang, J. Tabernero
Journal: Annals of Oncology (2022)
569P Pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: Real-life clinical experience
Authors: S. Poblete, M.A. Caulkins, C.L. Roche, A. Loecher, K. Attwood, N. Gaulin, K. Mager, P. Frederick, E. Zsiros
Journal: Annals of Oncology (2022)
1046P Homologous recombination deficiency (HRD) and genomic associations in non-small cell lung cancer (NSCLC) using a novel HRD signature (HRDsig)
Authors: J.W. Riess, R.W. Madison, K. Tolba, A.B. Schrock, G.R. Oxnard, E.S. Sokol
Journal: Annals of Oncology (2022)
547P Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study
Authors: A. Oaknin, B. Pothuri, L. Gilbert, R. Sabatier, J. Brown, S. Ghamande, C. Mathews, D. O'Malley, V. Boni, A. Gravina, S. Banerjee, R. Miller, J. Pikiel, M.R. Mirza, T. Duan, X. Han, S. Zildjian, N. Dewal, None J.Veneris, A.V. Tinker
Journal: Annals of Oncology (2022)
166P Adjuvant trastuzumab plus pertuzumab (TP) versus trastuzumab (T) alone in patients achieving pathologic complete response after chemotherapy with TP
Authors: J.H. Kim, Y. Kook, J.S. Jang, S.J. Bae, B.J. Chae, D. Shin, J.M. Ryu, J. Sohn, J. Jeong, S.G. Ahn
Journal: Annals of Oncology (2022)
861P Association of genetic variants in JAK/STAT signaling pathway with cutaneous melanoma susceptibility
Authors: C.S. Passos Lima, G.V.B. Gomez, G.J. Lourenço, L.M.O. Monteiro, R.S. Rocha, K.A.M. Fernández, J.A. Recio, J. Carron, C. Torricelli, L.O. Coser, A.L.R. Oliveira, A.M. Moraes
Journal: Annals of Oncology (2022)
931MO Final overall survival analysis of phase III study of pemetrexed/cisplatin versus vinorelbine/cisplatin for completely resected non-squamous non-small cell lung cancer: The JIPANG Study
Authors: K. Yoh, H. Kenmotsu, N. Yamamoto, T. Misumi, T. Takahashi, H. Saito, S. Sugawara, K. Yamazaki, K. Nakagawa, K. Sugio, T. Seto, S. Toyooka, H. Date, T. Mitsudomi, I. Okamoto, K. Yokoi, H. Saka, H. Okamoto, Y. Takiguchi, M. Tsuboi
Journal: Annals of Oncology (2022)
618O A phase I study of TRS005: An anti-CD20-MMAE antibody-drug conjugate, in relapsed or refractory b cell non-Hodgkin lymphoma
Authors: Y-K. Shi, Z-M. Li, Y. Qing, H. Zhang, Y. Jia, H. Jing, Y. Li, X. Tong, H. Liu, L. Li
Journal: Annals of Oncology (2022)
482P Safety, pharmacokinetic (PK), and pharmacodynamic profiles of the WEE1 inhibitor IMP7068 in patients (pts) with advanced solid tumors
Authors: C-C. Lin, J. Grewal, D. Sommerhalder, L-Y. Bai, G. Li, R. Schneider, L. Shen, Y-M. Yeh, R. Yin, H-C. Hsu, J.C. Baranda, C-Y. Hsieh, S.X. Cai, Y.E. Tian, N. Ma, H. Xia, C. Zhang, B. Li, M. Zhang, Z. Yu
Journal: Annals of Oncology (2022)
190P Staging strategies of newly diagnosed triple-negative breast cancer (TNBC): Comparison between CT scan and 18F-FDG-PET/CT
Authors: B. Riccò, B. Meduri, M. Venturelli, L. Cortesi, E. Barbieri, O. Ponzoni, L. Moscetti, C. Omarini, F. Piacentini, M. Dominici, A. Toss
Journal: Annals of Oncology (2022)
463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up
Authors: R.S. McDermott, C. van Tilburg, J.J. Lin, S. Kummar, D.S.W. Tan, C.M. Albert, J.D. Berlin, U.N. Lassen, F. Doz, B. Geoerger, L. Mascarenhas, N. Federman, R. Norenberg, L. Dima, C. Mussi, E.A. De La Cuesta, T. Laetsch, D.S. Hong, A.E. Drilon
Journal: Annals of Oncology (2022)
585P Trabectedin induces apoptosis regardless of acquired resistance to PARP inhibitors in BRCA2 mutant high grade ovarian cancer cell lines
Authors: J.A. Perez Fidalgo, P. Sanchez-Serrano, V. Heredia, J.J. Martinez Pretel, J. Hochstadt, M. Mendiola, A. Redondo Sanchez, O. Burgués, B. Pineda Merlo
Journal: Annals of Oncology (2022)
CN87 Pre-surgery demographic, clinical, and symptom characteristics associated with different self-reported cognitive processes in patients with breast cancer
Authors: Y-Y. Allemann-Su, M. Vetter, H. Koechlin, S.M. Paul, B.A. Cooper, K. Oppegaard, M. Melisko, J.D. Levine, Y. Conley, C. Miaskowski, M. Katapodi
Journal: Annals of Oncology (2022)